Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel for malignant airway obstruction (BROADWAY)
NCT02066103Completed
- Sponsor
- Mercator MedSystems
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Mercator MedSystems. Primary endpoints: Treatment safety at 12 weeks and Technical success at 1 day. Started Jul 2014; status: completed.
02
Drugs
paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02066103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066103.